Crestchem Limited reported an 18% revenue increase to ₹29.61 crore for FY26. The board has recommended a final dividend of ₹1.50 per share. A new subsidiary, Oleo Biosciences, has been formed with an approved investment of up to ₹2.25 crore.

Crestchem Limited

Revenue for FY26: ₹29.61 crore
Profit for FY26: ₹2.71 crore

Reader Takeaway: Strong revenue growth and dividend payout, but subsidiary's operational start is a key watch point.

What just happened

Crestchem Limited reported its financial results for the fiscal year 2025-26. The company saw its revenue from operations climb by approximately 18% to ₹29.61 crore, up from ₹25.08 crore in FY25. Profit for the period remained relatively stable at ₹2.71 crore, a slight decrease from ₹2.73 crore in the previous year. Basic Earnings Per Share (EPS) adjusted to ₹9.03 from ₹9.09. The Board of Directors has recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval.

Additionally, Crestchem has established a new subsidiary, OLEO BIOSCIENCES PRIVATE LIMITED, acquiring a 75% stake. The company's board has approved an investment of up to ₹2.25 crore in this subsidiary through various financial instruments.

Why this matters

The 18% revenue growth indicates expanding market reach or product demand for Crestchem. The recommended dividend offers a direct return to shareholders. The formation of a new subsidiary, Oleo Biosciences, suggests a strategic move towards diversification or expansion into new business areas, which could drive future growth if successful.

The backstory

Crestchem Limited operates in the chemical sector. In the previous fiscal year (FY25), the company reported revenues of ₹25.08 crore and a net profit of ₹2.73 crore. The EPS was ₹9.09.

What changes now

Shareholders will receive a ₹1.50 dividend per share if approved at the AGM. The company will now focus on developing its new subsidiary, Oleo Biosciences, which is currently awaiting commencement of commercial activities. The performance of this new entity will be critical for Crestchem's future growth trajectory.

Risks to watch

The primary concern highlighted is the status of the new subsidiary, Oleo Biosciences. It has not yet commenced commercial activities or significant financial transactions. Its future performance and contribution to Crestchem's overall financials remain uncertain until it becomes operational.

Peer comparison

(No specific peer comparison data was provided in the filing.)

Context metrics (time-bound)

Revenue from operations for FY26 stood at ₹29.61 crore, an 18% increase from ₹25.08 crore in FY25. Profit for FY26 was ₹2.71 crore, compared to ₹2.73 crore in FY25. Basic EPS was ₹9.03 for FY26 versus ₹9.09 for FY25.

What to track next

Investors should closely watch the operational commencement and financial performance of Oleo Biosciences Private Limited. Progress on this new venture and any further updates on dividend payouts will be key indicators.